Clinical Trial Update: A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating two doses of Avenciguat in people with liver cirrhosis and portal hypertension has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cirrhosis
• Portal Hypertension

Drugs mentioned

• Avenciguat

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hypertension, Portal | Phase 2 | Status: TERMINATED | Results posted: 2025-06-15